Future Planet backs Oxford Vaccine Company

“A biotechnology company whose research and intellectual property has helped to create the Oxford-AstraZeneca Covid vaccine has raised new investment from venture capitalists.

Oxford-based Vaccitech has agreed the funds – understood to be as much as £10million – from Future Planet Capital which also invests in health, climate change and education projects.

It is believed the capital will be used to help the roll-out of the Oxford vaccine, which could get UK approval as soon this week.”

Daily Mail, 26th December 2020

Future Planet was delighted to have welcomed Vaccitech to its Portfolio and today’s news demonstrates that cutting-edge technology from the world’s top universities has the potential to solve global social, economic and environmental challenges. 

Douglas Hansen-Luke, Executive Chairman - FPC

"FPC was founded with the vision of financing the brightest minds to profitably address global challenges. Today, as the Oxford vaccine’s results are published and an end to the coronavirus crisis is in sight, Future Planet is one step closer to realising its vision. We’re delighted to welcome Vaccitech to the Future Planet family.”

Bill Enright, CEO - Vaccitech 

“Future Planet and their practical and ethical policy of impact investing were a welcome investor at an important time for our company. Funding from Future Plant will help us to continue to progress our product candidates through clinical development.”

Ed Phillips, Head of Origination and Deal Lead - FPC

"Priced at the cost of a cup of coffee, and stored in a fridge, Vaccitech’s ChAdOx may represent the superhero of vaccine technologies we’ve all been waiting for. We are confident in the long-term prospects of the company’s platform. Not just for COVID, but also for prophylactic and therapeutic approaches for many other indications in oncology, infectious disease and chronic illness”

-
Future Planet Capital Limited is a global venture capital and impact investor, connecting the world's largest investors to the best minds in order to address global challenges. The firm is focussed on providing growth capital to leading entrepreneurs and businesses from the world’s top universities and has deployed over $100M on behalf of institutional investors to date. Future Planet's deal team was led by Ed Phillips, supported by Lyle Pentith. 

Vaccitech, Future Planet backed Oxford Spinout, Offers Global Path to End of COVID-19

Future Planet Backed Oxford Spinout Offers Global Path to End COVID

This week, interim Phase III data was released for the Oxford / AstraZeneca Vaccine, co-invented by our portfolio company Vaccitech. From late December, assuming the full dataset has been analysed and confirmed to meet formal regulatory requirements, AstraZeneca has announced that they believe they will be in a position to provide a vaccine for a quarter of the world's population. The vaccine will not just benefit the UK, EU and US who have ordered millions of doses, but the developing world, too. The Serum Institute of India has already begun producing 1 billion doses for the global south.

The results & data have now been independently verified in one of the world's leading medical journals, The Lancet. This is the first set of COVID-19 vaccine data to undergo scientific peer-review & demonstrates the efficacy & safety of the vaccine.

Future Planet made a direct investment into Vaccitech earlier this year. The clinical-stage biotech company owns rights to the viral vector technology, ChAdOx, which is used in the Oxford / AstraZeneca Vaccine. The company has a diverse pipeline in development across oncology, infectious disease and chronic illnesses affecting millions of people a year. 

Future Planet was delighted to have welcomed Vaccitech to its Portfolio and today’s news demonstrates that cutting-edge technology from the world’s top universities has the potential to solve global social, economic and environmental challenges. 

Douglas Hansen-Luke, Executive Chairman - FPC

"FPC was founded with the vision of financing the brightest minds to profitably address global challenges. Today, as the Oxford vaccine’s results are published and an end to the coronavirus crisis is in sight, Future Planet is one step closer to realising its vision. We’re delighted to welcome Vaccitech to the Future Planet family.”

Bill Enright, CEO - Vaccitech 

“Future Planet and their practical and ethical policy of impact investing were a welcome investor at an important time for our company. Funding from Future Plant will help us to continue to progress our product candidates through clinical development.”

Ed Phillips, Head of Origination and Deal Lead - FPC

"Priced at the cost of a cup of coffee, and stored in a fridge, Vaccitech’s ChAdOx may represent the superhero of vaccine technologies we’ve all been waiting for. We are confident in the long-term prospects of the company’s platform. Not just for COVID, but also for prophylactic and therapeutic approaches for many other indications in oncology, infectious disease and chronic illness”

-
Future Planet Capital Limited is a global venture capital and impact investor, connecting the world's largest investors to the best minds in order to address global challenges. The firm is focussed on providing growth capital to leading entrepreneurs and businesses from the world’s top universities and has deployed over $100M on behalf of institutional investors to date. Future Planet's deal team was led by Ed Phillips, supported by Lyle Pentith. 

Future Planet backs Oxford's Navenio

“Navenio exemplifies our investment thesis; best-in-class innovation from the world’s top university wrapped into a highly commercial product and company with the potential to scale its impact to help billions of lives. Having established partnerships with the NHS, Cleveland Clinic, and some of the world’s largest outsourcers, we believe the company is poised to revolutionise healthcare efficiency worldwide. Also, the core indoor geo-location engine developed at Oxford’s computer science lab has achieved what competing tech giants in the space have not, and we believe this will be hugely valuable cross-industry.”